The safety profile of Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs), including liraglutide, is of significant clinical relevance as these agents are increasingly used not only for type 2 diabetes but also for obesity management. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.